|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Immunology |
Internal Medicine C (Hematology and Oncology, Transplant Centre) (C.L., F.S., W.H.K., C.H., C.A.S., G.D.), Institute for Radiology (M.K.), and Institute for Pathology (S.V.), Ernst-Moritz-Arndt University, Greifswald, Germany
1 Address correspondence to William Krüger, Medizinische Klinik C (Hämatologie und Onkologie, Transplantationszentrum), Ernst-Moritz-Arndt-Universität Greifswald, Ferdinand-Sauerbruch-Straße, 17487 Greifswald, Germany (e-mail: william.krueger{at}uni-greifswald.de).
Abstract
Relapse of peripheral non-Hodgkin's lymphoma (NHL) in the central nervous system commonly has a poor prognosis. Graft-versus-leukemia effects (GvL) contribute substantially to eradication of hematological malignancies after allogeneic stem cell transplantation. Few data are available describing GvL activity within the brain. We report the case of a man allografted for peripheral NHL. On day +83 after transplantation a CNS relapse of the lymphoma occurred. The brain was irradiated with 44 Gy, anti-CD20 antibodies were given, and the immunosuppression was withdrawn. Subsequently, limited-stage, chronic graft-versus-host disease occurred. The lymphoma regressed completely, and the patient has been in continuous complete remission for 30 months. The favorable course suggests substantial contribution of immunomodulation to excellent outcome.
References
Casper, J., Knauf, W., Kiefer, T., Wolff, D., Steiner, B., Hammer, U., Wegener, R., Kleine, H.D., Wilhelm, S., Knopp, A., Hartung, G., Dolken, G., and Freund, M. (2004) Treosulfan and fludarabine: A new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 103, 725-731.
Classen, C.F., Debatin, K.M., Friedrich, W., and Schulz, A.S. (2003) Long-term remission of APL with a second allogeneic BMT after CNS relapse following HLA-identical allogeneic BMT. Bone Marrow Transplant. 32, 843-846.[CrossRef][Web of Science][Medline]
Curtis, R.E., Travis, L.B., Rowlings, P.A., Socie, G., Kingma, D.W., Banks, P.M., Jaffe, E.S., Sale, G.E., Horowitz, M.M., Witherspoon, R.P., Shriner, D.A., Weisdorf, D.J., Kolb, H.J., Sullivan, K.M., Sobocinski, K.A., Gale, R.P., Hoover, R.N., Fraumeni, J.F., Jr., and Deeg, H.J. (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 94, 2208-2216.
Dolken, G. (2001) Detection of minimal residual disease. Adv. Cancer Res. 82, 133-185.[Web of Science][Medline]
Hibi, S., Tsunamoto, K., Todo, S., Sawada, T., Ueda, Y., Taniwaki, M., Naya, M., Hojo, M., and Imashuku, S. (1997) Chimerism analysis on mononuclear cells in the CSF after allogeneic bone marrow transplantation. Bone Marrow Transplant. 20, 503-506.[CrossRef][Web of Science][Medline]
Kolb, H.J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M., and Wilmanns, W. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462-2465.
van Besien, K., Ha, C.S., Murphy, S., McLaughlin, P., Rodriguez, A., Amin, K., Forman, A., Romaguera, J., Hagemeister, F., Younes, A., Bachier, C., Sarris, A., Sobocinski, K.S., Cox, J.D., and Cabanillas, F. (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91, 1178-1184.
Varadi, G., Or, R., Kapelushnik, J., Naparstek, E., Nagler, A., Brautbar, C., Amar, A., Kirschbaum, M., Samuel, S., Slavin, S., and Siegal, T. (1999) Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk. Lymphoma 34, 185-190.[Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
